Fleming Pharma steps up radiation drug production

Fleming Pharmaceuticals has ramped up production of ThyroShield, a liquid potassium iodide product indicated for thyroid protection in radiation emergencies, to meet increased domestic and international demand.

ThyroShield is an over-the-counter iodide solution which, when taken orally, saturates the thyroid gland so that radioactive iodine cannot be absorbed. The drug is effective for babies and children, who are most at risk during radiation exposure, according to Fenton, Mo.-based Fleming Pharmaceuticals.

The company has qualified a new potassium iodide supplier, established new agreements with vendors to shorten lead times needed to complete orders for ThyroShield package components and identified production line logistics to fulfill any significant new orders for ThyroShield.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.